CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced that the company will be added to the Russell 2000(R) Index, effective June 25, 2021, after the close of the U.S. equity markets. CNSP will be added following the annual reconstitution of the Russell stock indexes. According to the announcement, the Russell 2000 Index, which is a subset of the Russell 3000(R) Index, measures the performance of the small-cap segment of the equity market in the United States and includes an estimated 2,000 of the smallest securities based on a combination of their market cap and current index membership. Investment managers and institutional investors commonly rely on the Russell Index for index funds and as benchmarks for active investment strategies; approximately $9 trillion in assets are benchmarked against Russell’s U.S. indexes. The indexes are part of global index leader FTSE Russell, which provides innovative benchmarking, analytics and data solutions for investors worldwide. “We are pleased to meet this noteworthy milestone and be included in the Russell 2000 Index,” said CNS Pharmaceuticals CEO John Climaco in the press release. “As our team continues to drive our clinical program forward for the treatment of glioblastoma multiforme (‘GBM’), we believe this inclusion well-positions us to drive market awareness. We are honored to be listed among our industry peers on what is considered to be a widely respected performance benchmark for small-cap companies. We look forward to leveraging the access and positioning this inclusion brings to unlock additional value.”
To view the full press release, visit https://ibn.fm/Lsa9D
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer.
Additionally, the company is advancing the development of its WP1244 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500 times more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain cancers, pancreatic, ovarian, and lymphomas. For more information about the company, please visit www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.